ALSO READSuven Life Sciences gets livelier after securing product patents Suven Life Sciences secures two product patents for its NCEs Suven Life Sciences Q2 net up 20 pc to Rs 32 cr Suven Life Sciences sizzles after securing a product patent Suven Life Sciences extends gains after securing product patent
From Norway and EurasiaSuven Life Sciences announced the grant of one (1) product patent from Eurasia (028038) and one (1) product patent from Norway (341252) corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2034 and 2026 respectively.
The granted claims of the patents include the class of selective 5-HT6 compounds and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, Attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson and Schizophrenia.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)